NSE: ANTHEM · BSE: 544449 · ISIN INE0CZ201020
Anthem Biosciences Limited stock analysis
Anthem Biosciences Limited ranks #85 in the TickerSutra evidence-ranked universe with a score of 73/100 and 89% data confidence. The latest captured fundamentals show ROCE of 30.4%, quarterly sales growth of -22.6% and quarterly profit growth of -11.7%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 30.4%
- Low debt/equity of 0.02×
- Strong CFO/EBITDA of 1.01×
- 26.2% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,231cr | ₹565cr | ₹406cr | 46.0% |
| 2023 | ₹1,057cr | ₹431cr | ₹385cr | 41.0% |
| 2024 | ₹1,419cr | ₹506cr | ₹367cr | 36.0% |
| 2025 | ₹1,845cr | ₹672cr | ₹451cr | 36.0% |
| 2026 | ₹2,124cr | ₹834cr | ₹592cr | 39.0% |
| TTM | ₹2,002cr | ₹793cr | ₹576cr | 40.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Third is the ability to be regulatory compliant. Your track record on regulatory compliance is also really important to our customers. On all these three counts, if you score high, you're very likely to be favored by the customer.
We've done enough trials and enough scale -up activities to know that our product once we have permission, we'll be able to supply people. As we've said earlier, that we've sampled almost all the big players , and many of them are waiting for us to have the approval from CDSCO , and then they're ready to go. So , that's something that we are is waiting to happen and it will happen sometime this year for sure.
Our focus has always been in terms of how we optimize on costs. Across the three metrics on the cost side, raw material margin we have been consistently increasing, and that's largely focused on yield improvement as well as backward integration, and of most of the key intermediate. Anthem Biosciences Limited July 22, 2026 Page 13 of 17 Our employee cost has been amongst the lowest vis -a-vis as a percentage of sales
The next question is from the line of Tushar Manudhane from Motilal Oswal Financial Services. Tushar Manudhane: Sir, just extending the previous participant's question, this existing customer contract, was this the manufacturing commercial contract or was this like a scale -up for product approval, if you could share that point? Gawir Baig: It's a development contract which we are working with the emerging biotech wh
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…